Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™ Jul 16, 2021 08:30AM
Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021 Jul 8, 2021 08:00AM
Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021 Jun 30, 2021 08:00AM
Horizon Therapeutics (HZNP) Enrolls First Patient in Phase 2 Trial of HZN-7734 for the Treatment of Systemic Lupus Erythematosus Jun 29, 2021 08:02AM
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus Jun 29, 2021 08:00AM
View Older Stories

Jun 28, 2021 09:00AM Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jun 21, 2021 07:32AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 18, 2021 12:32PM Horizon Therapeutics (HZNP) Announces Multiple Presentations on NMOSD at EAN
Jun 18, 2021 12:30PM Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Jun 17, 2021 07:06AM Horizon Therapeutics (HZNP) Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 17, 2021 07:00AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 2, 2021 08:00AM Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
May 27, 2021 08:00AM Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
May 24, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
May 21, 2021 08:00AM Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology
May 20, 2021 08:30AM Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®
May 13, 2021 11:30AM Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company
May 6, 2021 04:30PM Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
May 6, 2021 08:34AM Horizon Therapeutics (HZNP) Announces New Analysis of UPLIZNA for Neuromyelitis Optica Spectrum Disorder Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:30AM New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:00AM Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
May 5, 2021 07:00AM Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc
Apr 27, 2021 08:00AM Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
Apr 16, 2021 08:30AM New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 16, 2021 08:03AM Horizon Therapeutics (HZNP) Announces New Integrated Data and Follow-up Outcomes From Two TEPEZZA Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 16, 2021 08:00AM New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 12, 2021 08:30AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Apr 8, 2021 08:00AM Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
Apr 7, 2021 08:03AM Horizon Therapeutics (HZNP) RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA with Immunomodulator Mycophenolate Mofetil
Apr 7, 2021 08:00AM RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
Apr 5, 2021 08:36AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in People With Neuromyelitis Optica Spectrum Disorder to be Presented at AAN's 73rd Annual Meeting
Apr 5, 2021 08:30AM New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
Mar 30, 2021 07:34AM Horizon Therapeutics (HZNP) to Resupply Market With TEPEZZA for the Treatment of Thyroid Eye Disease Beginning in April
Mar 30, 2021 07:30AM Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
Mar 29, 2021 10:05AM Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership
Mar 25, 2021 08:00AM First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
Mar 24, 2021 08:16AM Horizon Therapeutics (HZNP) Announces UPLIZNA Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder
Mar 24, 2021 08:15AM UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2021 08:00AM Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
Mar 15, 2021 08:50AM Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
Mar 12, 2021 08:45AM Horizon Therapeutics plc Named Number One Best Workplace in Biopharma
Mar 11, 2021 03:00AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Feb 26, 2021 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
Feb 25, 2021 04:05PM Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
Feb 24, 2021 07:00AM Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
Feb 22, 2021 09:30AM New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
Feb 4, 2021 01:00AM Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 4, 2021 12:58AM Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 3, 2021 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Feb 1, 2021 07:03AM Horizon Therapeutics (HZNP) to Acquire Viela Bio (VIE) for $53 Per Share in $3.05 Billion Deal
Feb 1, 2021 07:00AM Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
Jan 11, 2021 07:04AM Horizon Therapeutics (HZNP) Provides Preliminary 2020 Financial Results
Jan 11, 2021 07:00AM Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New K
View Older Stories